<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lacosamide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lacosamide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lacosamide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10268" href="/d/html/10268.html" rel="external">see "Lacosamide: Drug information"</a> and <a class="drug drug_patient" data-topicid="12182" href="/d/html/12182.html" rel="external">see "Lacosamide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6786825"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Motpoly XR;</li>
<li>Vimpat</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868985"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Lacosamide;</li>
<li>AG-Lacosamide;</li>
<li>APO-Lacosamide;</li>
<li>Auro-Lacosamide;</li>
<li>JAMP-Lacosamide;</li>
<li>MAR-Lacosamide;</li>
<li>MINT-Lacosamide;</li>
<li>NRA-Lacosamide;</li>
<li>Pharma-Lacosamide;</li>
<li>SANDOZ Lacosamide;</li>
<li>TEVA-Lacosamide;</li>
<li>Vimpat</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F9406528"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F6790645"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7da4c65-4d37-47cf-9f8d-0c86c1a7d4bb">Seizures, partial onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, partial (focal) onset:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients already on a single antiseizure medication and converting to lacosamide monotherapy, maintain the maintenance dose for 3 days before beginning withdrawal of the concomitant antiseizure drug. Gradually taper the concomitant antiseizure drug over ≥6 weeks. When switching from oral to IV formulations in patients weighing ≥6 kg, the total daily dose and frequency should be the same; IV therapy should only be used temporarily. Clinical study experience of IV lacosamide is limited to 5 days of consecutive treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monotherapy and adjunctive therapy</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;6 kg: In patients &lt;6 kg, oral and intravenous dosing is different; use caution.</p>
<p style="text-indent:-2em;margin-left:10em;">IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Initial: IV: 0.66 mg/kg/dose 3 times daily; may be increased at weekly intervals by 0.66 mg/kg/dose 3 times daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance: IV: 2.5 to 5 mg/kg/dose 3 times daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Oral:</p>
<p style="text-indent:-2em;margin-left:12em;">Initial: Oral (immediate release): 1 mg/kg/dose twice daily; may be increased at weekly intervals by 1 mg/kg/dose twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance: Oral (immediate release): 3.75 to 7.5 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">6 to &lt;30 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (immediate release), IV: 1 mg/kg/dose twice daily; may be increased at weekly intervals by 1 mg/kg/dose twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance: Oral (immediate release), IV: 3 to 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">30 to &lt;50 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (immediate release), IV: 1 mg/kg/dose twice daily; may be increased at weekly intervals by 1 mg/kg/dose twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance: Oral (immediate release), IV: 2 to 4 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">Immediate-release preparations:</p>
<p style="text-indent:-2em;margin-left:12em;">Initial (monotherapy and adjunctive therapy): Oral (immediate release), IV: 50 mg twice daily; may be increased at weekly intervals of 50 mg twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Monotherapy maintenance:</i> Oral (immediate release), IV: 150 to 200 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Adjunctive therapy maintenance</i>: Oral (immediate release), IV: 100 to 200 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Extended-release preparations:</p>
<p style="text-indent:-2em;margin-left:12em;">Initial (monotherapy and adjunctive therapy): Oral (extended release [eg, Motpoly XR]): 100 mg once daily; may be increased at weekly intervals in 100 mg/day increments based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:12em;">Maintenance:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Monotherapy maintenance: </i>Oral (extended release [eg, Motpoly XR]): 300 to 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Adjunctive therapy maintenance: </i>Oral (extended release [eg, Motpoly XR]): 200 to 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Immediate-release preparations:</span></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Monotherapy:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (immediate release), IV: 100 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Alternate initial dosage: Oral (immediate release), IV: Loading dose: 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. <b>Note:</b> Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance: Oral (immediate release), IV: 150 to 200 mg twice daily. <b>Note: </b>Doses up to 300 mg twice daily may provide additional benefit in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27889312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27889312'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Adjunctive therapy:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (immediate release), IV: 50 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Alternative initial dosage: Oral (immediate release), IV: Loading dose of 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. <b>Note:</b> Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: Oral (immediate release), IV: 100 to 200 mg twice daily.<b> Note: </b>Doses up to 300 mg twice daily may provide additional benefit in some patients; however, risk of adverse effects may be greater when higher doses of lacosamide are used in combination with other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20132285','lexi-content-ref-27430392','lexi-content-ref-26077821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20132285','lexi-content-ref-27430392','lexi-content-ref-26077821'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Extended-release preparations</span>
<span style="text-decoration: underline">:</span></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Monotherapy:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (extended release [Motpoly XR]): 200 mg once daily; may be increased at weekly intervals in 100 mg/day increments based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance: Oral (extended release [Motpoly XR]): 300 to 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Adjunctive therapy: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (extended release [Motpoly XR]): 100 mg once daily; may be increased at weekly intervals in 100 mg/day increments based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance: Oral (extended release [Motpoly XR]): 200 to 400 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a829c9d-6f9d-4701-aeab-ab52a78194c5">Seizures, primary generalized tonic-clonic; adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, primary generalized tonic-clonic; adjunctive therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When switching from oral to IV formulations, the total daily dose and frequency should be the same; IV therapy should only be used temporarily. Clinical study experience of IV lacosamide is limited to 5 days of consecutive treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents &lt;17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate-release preparations:</p>
<p style="text-indent:-2em;margin-left:8em;">11 to &lt;30 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (immediate release), IV: 1 mg/kg/dose twice daily; may be increased at weekly intervals by 1 mg/kg/dose twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance: Oral (immediate release), IV: 3 to 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">30 to &lt;50 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (immediate release), IV: 1 mg/kg/dose twice daily; may be increased at weekly intervals by 1 mg/kg/dose twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance: Oral (immediate release), IV: 2 to 4 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: Oral (immediate release), IV: 50 mg twice daily; may be increased at weekly intervals of 50 mg twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance: Oral (immediate release), IV: 100 to 200 mg twice daily. <b>Note: </b>In clinical trials of adjunctive therapy in adults, doses higher than 400 mg/day were not more effective and were associated with more adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate-release preparations:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: Oral (immediate release), IV: 50 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternative initial dosage: Oral (immediate release), IV: Loading dose of 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. <b>Note:</b> Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: Oral (immediate release), IV: 100 to 200 mg twice daily.<b> Note: </b>In clinical trials of adjunctive therapy in adults, doses higher than 400 mg/day were not more effective and were associated with more adverse reactions.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff3cf598-02e2-4692-bca6-8cd090573a46">Seizures, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, refractory:</b> Limited data available: Infants ≥6 months, Children, and Adolescents: Oral (immediate release), IV: Initial: 0.5 to 1 mg/kg/dose twice daily (usual maximum initial dose: 50 mg/dose); may titrate by 0.5 to 1 mg/kg/dose weekly based on response and tolerability. Mean maintenance dose: 3.6 mg/kg/dose; reported range: 0.5 to 10 mg/kg/dose twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23193979','lexi-content-ref-31462582','lexi-content-ref-21406334','lexi-content-ref-24479878','lexi-content-ref-24129195','lexi-content-ref-29428899','lexi-content-ref-23298605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23193979','lexi-content-ref-31462582','lexi-content-ref-21406334','lexi-content-ref-24479878','lexi-content-ref-24129195','lexi-content-ref-29428899','lexi-content-ref-23298605'])">Ref</a></span>). <b>Note</b>: Lacosamide may be more effective in refractory focal seizures as compared to generalized seizures, and efficacy may decrease after initial response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27430392','lexi-content-ref-29428899']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27430392','lexi-content-ref-29428899'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3cf4716-2d40-4dd4-9822-7d4ea864180d">Status epilepticus, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus, refractory:</b> Limited data available: <b>Note:</b> Optimal place in therapy not defined; variable regimens reported; use is typically reported after failure of ≥2 to 3 agents; dosing based on retrospective case series (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26810009','lexi-content-ref-24836405','lexi-content-ref-27241232','lexi-content-ref-29017081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26810009','lexi-content-ref-24836405','lexi-content-ref-27241232','lexi-content-ref-29017081'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: 5 to 10 mg/kg/dose as a single dose, infused over 15 to 30 minutes; reported range for loading dose: 2 to 11 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26810009','lexi-content-ref-24836405','lexi-content-ref-27241232','lexi-content-ref-32822230','lexi-content-ref-29017081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26810009','lexi-content-ref-24836405','lexi-content-ref-27241232','lexi-content-ref-32822230','lexi-content-ref-29017081'])">Ref</a></span>). Usual maximum loading dose in adults: 400 mg/dose; doses up to 600 mg/dose have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274','lexi-content-ref-28295226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274','lexi-content-ref-28295226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: IV: 6.5 mg/kg/dose twice daily; range of reported maintenance doses: 0.5 to 7 mg/kg/dose twice daily; usual adult maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24836405','lexi-content-ref-32822230','lexi-content-ref-29017081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24836405','lexi-content-ref-32822230','lexi-content-ref-29017081'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy: </b>There is currently no standard method for the withdrawal of antiseizure medications in pediatric patients. Successful discontinuation of an antiseizure medication is dependent on several factors including but not limited to: Time of seizure freedom, underlying reason for the seizures, neuroimaging abnormalities, underlying neurodevelopmental status, and medication to be withdrawn (including dose, duration of therapy, and other pharmacokinetic/dynamic considerations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31990368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31990368'])">Ref</a></span>). Avoid abrupt discontinuation; gradually withdraw over ≥1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114942"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: Immediate release, extended release:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Titrate dose with caution; use the Schwartz equation for calculation in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate renal impairment (CrCl ≥30 mL/minute/1.73 m<sup>2</sup>): No dose adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe renal impairment (CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>): Maximum daily dose: Reduce dose to 75% of maximum dose, not to exceed 300 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) requiring hemodialysis: Maximum daily dose: Reduce dose to 75% of maximum dose. Removed by hemodialysis; after 4-hour hemodialysis treatment, a supplemental dose of up to 50% should be considered.</p></div>
<div class="block dohp drugH1Div" id="F51114943"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: Titrate dose with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate hepatic impairment: Maximum daily dose: Reduce dose to 75% of maximum dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Use is not recommended.</p></div>
<div class="block doa drugH1Div" id="F6790646"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10268" href="/d/html/10268.html" rel="external">see "Lacosamide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31008289-31f3-4083-91b3-0190ad6d466a">Focal onset seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal (partial) onset seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Monotherapy:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immediate release (tablets, oral solution)</i>: Initial: 50 to 100 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability to a maintenance dose of 150 to 200 mg twice daily. Doses up to 600 mg/day may provide additional benefit in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27889312','lexi-content-ref-24915838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27889312','lexi-content-ref-24915838'])">Ref</a></span>). Alternatively, may give 200 mg loading dose followed 12 hours later by 100 mg twice daily with same titration schedule. Administer loading doses under medical supervision due to increased incidence of CNS adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Extended release (capsules): </i>Initial: 200 mg once daily; may be increased at weekly intervals by 100 mg once daily based on response and tolerability to a maintenance dose of 300 to 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 50 to 100 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability to a maintenance dose of 150 to 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Doses up to 600 mg/day may provide additional benefit in some patients based on data with the oral formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27889312','lexi-content-ref-17635557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27889312','lexi-content-ref-17635557'])">Ref</a></span>). Alternatively, may give 200 mg loading dose followed 12 hours later by 100 mg twice daily with same titration schedule. Administer loading doses under medical supervision due to increased incidence of CNS adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22708895','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22708895','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adjunctive therapy:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immediate release (tablets, oral solution)</i>: Initial: 50 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability to a maintenance dose of 100 to 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19183227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19183227'])">Ref</a></span>). Alternatively, may give 200 mg loading dose followed 12 hours later by 100 mg twice daily with same titration schedule. Doses up to 600 mg/day may provide additional benefit in some patients; however, risk of adverse effects may be greater when higher doses of lacosamide are used in combination with other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17635557','lexi-content-ref-20132285','lexi-content-ref-26077821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17635557','lexi-content-ref-20132285','lexi-content-ref-26077821'])">Ref</a></span>). Administer loading doses under medical supervision due to increased incidence of CNS adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Extended release (capsules):</i> Initial: 100 mg once daily; may be increased at weekly intervals by 100 mg once daily up to a maintenance dose of 200 to 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 50 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability to a maintenance dose of 100 to 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Alternatively, may give 200 mg loading dose followed 12 hours later by 100 mg twice daily with same titration schedule. Doses up to 600 mg/day may provide additional benefit in some patients based on data with the oral formulation; however, risk of adverse effects may be greater when higher doses of lacosamide are used in combination with other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17635557','lexi-content-ref-20132285','lexi-content-ref-26077821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17635557','lexi-content-ref-20132285','lexi-content-ref-26077821'])">Ref</a></span>). Administer loading doses under medical supervision due to increased incidence of CNS adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22708895','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22708895','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="384a764e-de55-4b63-b918-c350f4d4f02e">Primary generalized tonic-clonic seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary generalized tonic-clonic seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adjunctive therapy:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral</b>
<b>(immediate release tablets, oral solution), IV</b>: Initial: 50 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability to a maintenance dose of 100 to 200 mg twice daily. Alternatively, may give 200 mg loading dose followed 12 hours later by 100 mg twice daily with same titration schedule. Administer loading doses under medical supervision due to increased incidence of CNS adverse reactions.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 200 to 400 mg as a single dose followed by a maintenance dose of 200 to 400 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jirsch.1','lexi-content-ref-28919386','lexi-content-ref-22528274','lexi-content-ref-23533010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jirsch.1','lexi-content-ref-28919386','lexi-content-ref-22528274','lexi-content-ref-23533010'])">Ref</a></span>); some patients may require up to 600 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28295226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28295226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The Neurocritical Care Society recommends an administration rate of 200 mg over 15 minutes; however, some experts administer doses up to 400 mg at a rate of ≤80 mg/minute (eg, 400 mg over 5 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29949010','lexi-content-ref-19816574','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29949010','lexi-content-ref-19816574','lexi-content-ref-22528274'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy</b>: Avoid abrupt discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (tablets, oral solution), IV: </i>Withdraw gradually in weekly intervals by 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17635557','lexi-content-ref-20132285','lexi-content-ref-19183227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17635557','lexi-content-ref-20132285','lexi-content-ref-19183227'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release (capsules)</i>: Withdraw gradually over ≥1 week.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990596"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV, oral (IR</b>
<b> tablets, oral solution; ER capsules)</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: Note: </b>Renal function may be estimated using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: Initial and maintenance: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: No dosage adjustment necessary; base initiation and titration schedule on clinical response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance: Administer up to 75% of the indication-specific maximum dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (50% after a 4-hour hemodialysis session) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737404'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: No dosage adjustment necessary; administer a supplemental dose (up to 50%) after each hemodialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Administer up to 75% of the indication-specific maximum dose; administer a supplemental dose (up to 50%) after each hemodialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Administer up to 75% of the indication-specific maximum dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33855736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33855736'])">Ref</a></span>). Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, seizure control) and consideration of initial loading doses, if applicable. Close monitoring of response and adverse reactions (eg, CNS effects) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial and maintenance: No dosage adjustment is likely necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>) since lacosamide is significantly removed by CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29160945','lexi-content-ref-33855736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29160945','lexi-content-ref-33855736'])">Ref</a></span>). However, at higher effluent flow rates (eg, &gt;4,000 mL/hour), some patients may require higher than normal doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33855736','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33855736','lexi-content-ref-Expert.DOR'])">Ref</a></span>); may consider therapeutic drug monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, seizure control) and consideration of initial loading doses, if applicable. Close monitoring of response and adverse reactions (eg, CNS effects) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: No dosage adjustment necessary; administer a supplemental dose (up to 50%) after each PIRRT session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Administer up to 75% of the indication-specific maximum dose; administer a supplemental dose (up to 50%) after each PIRRT session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987980"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV, oral (</b>
<b>IR tablets, oral solution; ER capsules): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate hepatic impairment: Administer up to 75% of the indication-specific maximum dose; base initiation and titration schedule on clinical response and tolerability.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Use is not recommended.</p></div>
<div class="block arsc drugH1Div" id="F56342305"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lacosamide may cause <b>cardiac arrhythmias</b> including, but not limited to <b>bradycardia</b>, <b>atrioventricular block</b>, and tachyarrhythmias such as <b>atrial fibrillation</b>,<b> atrial flutter</b>, and <b>ventricular tachycardia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30723940','lexi-content-ref-31914330','lexi-content-ref-27054272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30723940','lexi-content-ref-31914330','lexi-content-ref-27054272'])">Ref</a></span>). Cardiovascular (CV) adverse reactions are rare but potentially life-threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31914330','lexi-content-ref-25933358','lexi-content-ref-27054272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31914330','lexi-content-ref-25933358','lexi-content-ref-27054272'])">Ref</a></span>). Restoration of normal cardiac rhythm has occurred following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28343443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28343443'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; acts predominantly by enhancing the slow inactivation of voltage-dependent sodium channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19816574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19816574'])">Ref</a></span>). Sodium channel-blocking drugs such as lacosamide cause slowing of conduction velocity in cardiac tissues, predominantly in non-nodal tissues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23360388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23360388'])">Ref</a></span>). Specifically, lacosamide appears to disrupt the SCN5A channel for which mutations have been previously linked to Brugada syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25688050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25688050'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Exact onset is unknown. Some literature suggests onset may occur during IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28343443','lexi-content-ref-30723940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28343443','lexi-content-ref-30723940'])">Ref</a></span>), but some cases reported abnormal ECG after chronic oral use as well (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23360388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23360388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31914330','lexi-content-ref-27054272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31914330','lexi-content-ref-27054272'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• CV comorbidities (eg, CV disease, cardiac conduction abnormalities) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31914330','lexi-content-ref-27054272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31914330','lexi-content-ref-27054272'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31914330','lexi-content-ref-27054272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31914330','lexi-content-ref-27054272'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other proarrhythmic medications (eg, antiarrhythmics, other antiseizure medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27054272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27054272'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">CNS effects, such as <b>dizziness</b>, <b>drowsiness</b>, <b>headache</b>, and <b>ataxia</b> are common and expected adverse reactions that may occur with lacosamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27054272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27054272'])">Ref</a></span>). Other CNS-related adverse reactions may include <b>confusion</b>, <b>cognitive dysfunction</b>, <b>memory impairment</b>, <b>paresthesia</b>, and <b>sleep disturbance</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22698379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22698379'])">Ref</a></span>). CNS effects may be minimized by gradual dose titration, and some may regress spontaneously during continuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22832500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22832500'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22832500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22832500'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; more likely to occur in the early stages of treatment (~3 months). One report showed incidence of dizziness to be 3 to 4 times higher in the titration period than in the maintenance period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31914330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31914330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31914330','lexi-content-ref-22832500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31914330','lexi-content-ref-22832500'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31914330','lexi-content-ref-22832500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31914330','lexi-content-ref-22832500'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22832500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22832500'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent antiseizure medications or medications that cause sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22832500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22832500'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A variety of delayed hypersensitivity reactions, ranging from mild with <b>skin rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23293881','lexi-content-ref-31997613','lexi-content-ref-25035958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23293881','lexi-content-ref-31997613','lexi-content-ref-25035958'])">Ref</a></span>) to severe cutaneous adverse reactions (SCARs), including <b>Stevens-Johnson syndrome/toxic epidermal necrolysis</b> and <b>drug reaction with eosinophilia and systemic symptoms </b>(DRESS) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29588957','lexi-content-ref-27017922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29588957','lexi-content-ref-27017922'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. Delayed hypersensitivity reactions, including rashes (often maculopapular) and SCARs, are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed hypersensitivity reactions: Varied; a diffuse skin rash developed in 1 patient after 8 days of treatment with lacosamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25035958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25035958'])">Ref</a></span>). SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-27017922','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-27017922','lexi-content-ref-NICE.1'])">Ref</a></span>); reexposure to the same or similar drug may lead to more rapid onset (usually with 1 to 4 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-29588957','lexi-content-ref-27086495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-29588957','lexi-content-ref-27086495'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Cross-reactivity has not been well defined. In one report, DRESS developed rapidly after initiation of lacosamide following a previous reaction with phenobarbital. Cross-reactivity with phenobarbital was hypothesized based on the common aromatic ring in phenobarbital and lacosamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29588957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29588957'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation/tendencies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antiseizure medications have been associated with suicidal ideation and suicidal tendencies. However, the FDA meta-analysis has been criticized due to several important limitations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496806','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496806','lexi-content-ref-22994856'])">Ref</a></span>). The risk of suicide is increased in epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453718'])">Ref</a></span>), but the occurrence of suicidal ideation/tendencies in epilepsy is multifactorial. While some antiseizure medications (but not all) have been associated with treatment-emergent psychiatric effects such as anxiety and depression, other factors such as postictal suicidal behavior and pertinent patient history must also be evaluated to provide an accurate assessment of risk for any individual drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>). Suicidal ideation and suicidal tendencies have been reported in association with lacosamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27054272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27054272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; peak incidence of suicidality across antiseizure medications (not specific to individual agents) has been noted to occur between 1 and 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254','lexi-content-ref-20388896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254','lexi-content-ref-20388896'])">Ref</a></span>). A review of clinical trials noted that risk extended from 1 week to 24 weeks of therapy, corresponding to the duration of most trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889','lexi-content-ref-18698874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889','lexi-content-ref-18698874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use in conditions other than epilepsy or bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• In patients with bipolar disorder, risk for repeat suicide attempt was increased in patients with alcohol/substance abuse disorder, rapid cycling, and earlier age at onset of first manic episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F6790406"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with immediate-release oral formulations, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (7% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (16% to 30%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 1</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (5% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 2</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, headache (11% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 3</a>)</span><span class="table-link" style="display:none;">Headache</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Lacosamide: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lacosamide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lacosamide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tonic-clonic seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution and tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution and tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">270</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Lacosamide: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lacosamide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lacosamide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tonic-clonic seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution and tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution and tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">270</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption style="text-align:center;">
<b>Lacosamide: Adverse Reaction: Headache</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lacosamide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lacosamide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tonic-clonic seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution and tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution and tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">270</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (5%), vomiting (6% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Irritation at injection site (IV: 1%), pain at injection site (IV: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (2%), asthenia (2%), ataxia (4% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Ataxia table link" class="lexi-table-link" data-table-id="lexi-content-ataxia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ataxia')">table 4</a>)</span><span class="table-link" style="display:none;">Ataxia</span>, balance impairment (1% to 5%), depression (2%), fatigue (7%), tremor (6%), vertigo (3% to 5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ataxia" frame="border" id="lexi-content-ataxia" rules="all">
<caption style="text-align:center;">
<b>Lacosamide: Adverse Reaction: Ataxia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lacosamide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lacosamide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution and tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">471</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral solution and tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">270</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">364</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (9%), diplopia (6% to 10%), nystagmus disorder (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Laceration (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, first-degree atrioventricular block</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (IV)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephritis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, oral hypoesthesia, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebellar syndrome, dysarthria, euphoria, falling, hypoesthesia, intoxicated feeling</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (Steinhoff 2016), atrial fibrillation (Steinhoff 2016), atrial flutter (Steinhoff 2016), atrioventricular block (Steinhoff 2016), cardiac arrhythmia (Steinhoff 2016), complete atrioventricular block (Steinhoff 2016), palpitations (Steinhoff 2016), prolongation P-R interval on ECG (Steinhoff 2016), prolonged QT interval on ECG (Steinhoff 2016), syncope (Steinhoff 2016), ventricular tachycardia (Steinhoff 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (Kim 2020), Stevens-Johnson syndrome (Kardaun 2016), toxic epidermal necrolysis (Kardaun 2016), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (Steinhoff 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (Verrotti 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Shibata 2021), neutropenia (Rao 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Goodwin 2011), drug reaction with eosinophilia and systemic symptoms (Fong 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (Flores 2012), agitation, amnesia (Steinhoff 2016), cognitive dysfunction (Steinhoff 2016), confusion (Steinhoff 2016), depressed mood (Steinhoff 2016), disturbance in attention (Steinhoff 2016), hallucination (Flores 2012), irritability (Verrotti 2013), memory impairment (Steinhoff 2016), mood changes (Flores 2012), paresthesia (Verrotti 2013), psychosis, sleep disturbance (Flores 2012), suicidal ideation (Steinhoff 2016), suicidal tendencies (Steinhoff 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (Madani 2020), panniculitis (Zhao 2022)</p></div>
<div class="block coi drugH1Div" id="F6790319"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to lacosamide or any component of the formulation; second- or third-degree atrioventricular (AV) block (current or history of).</p></div>
<div class="block war drugH1Div" id="F6790403"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Not recommended for use in patients with severe hepatic impairment; dosage adjustment required for mild to moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular conditions: Blurred vision and diplopia may occur during therapy. Patients with persistent visual disturbances may need further assessment. Consider increased monitoring in patients with preexisting ocular conditions or vision-related issues.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with renal impairment; dosage adjustment required for severe renal impairment (CrCl ≤30 mL/minute) and supplementation may be necessary in hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually (≥1 week) to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878723"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In vitro data has shown lacosamide interferes with collapsing response mediator protein-2 (CRMP-2), a protein involved with neuronal differentiation and control of axonal outgrowth; potential effect on CNS development cannot be excluded. Lacosamide administered to neonatal and juvenile rats resulted in decreased brain weights and long-term neurobehavioral changes including learning and memory deficits. Studies of the effects of lacosamide on human CNS development are needed before this medication can be recommended for routine use in pediatric patients &lt;4 years of age.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F6790656"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motpoly XR: 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motpoly XR: 200 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 200 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 10 mg/mL (200 mL, 465 mL [DSC]) [contains aspartame, methylparaben, polyethylene glycol (macrogol), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (5 mL, 10 mL, 15 mL, 20 mL, 200 mL, 465 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 50 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 200 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 150 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F6790309"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16321857"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Motpoly XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $25.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $25.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $25.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lacosamide Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/20 mL (per mL): $2.40 - $4.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lacosamide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.44 - $2.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vimpat Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/20 mL (per mL): $5.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vimpat Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $2.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lacosamide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.48 - $12.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.46 - $19.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $2.95 - $20.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $2.95 - $20.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Vimpat Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $14.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $22.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $23.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $23.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868986"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 200 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 50 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vimpat: 200 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 150 mg, 200 mg</p></div>
<div class="block csi drugH1Div" id="F9590984"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-V</p></div>
<div class="block admp drugH1Div" id="F52614284"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Solution: Should be administered with a calibrated measuring device (not a household teaspoon or tablespoon). May be administered via a nasogastric or gastrostomy tube. Discard any remaining product in bottle after 6 months from first opening.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets: Swallow tablets whole; do not divide.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Motpoly XR: Capsules: Swallow capsules whole; do not open, chew, or crush.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Administer over 30 to 60 minutes to minimize adverse effects; may be administered undiluted or diluted in compatible diluent. Infusion times &lt;30 minutes are generally not recommended in pediatric patients; in adults, infusions of 15 minutes may be used if necessary. IV infusion may cause bradycardia, AV blocks, and ventricular tachyarrhythmias; monitor closely. Rapid administration has been associated with higher CNS adverse effects (eg, dizziness, somnolence, paresthesia); monitor closely.</p></div>
<div class="block adm drugH1Div" id="F6790652"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infusion: According to the manufacturer, administer over 30 to 60 minutes to minimize adverse effects; infusions of 15 minutes may be used if needed. IV administration has been used for up to 5 days. Administer loading doses under medical supervision due to increased risk of adverse reactions, including cardiovascular and CNS. Can be administered without further dilution or may be mixed with compatible diluents (NS, LR, D5W).</p>
<p style="text-indent:-2em;margin-left:4em;">Bolus (off label): Doses up to 400 mg may be administered undiluted at ≤80 mg/minute (eg, 400 mg over 5 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29949010','lexi-content-ref-19816574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29949010','lexi-content-ref-19816574'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsules, oral solution, tablets: May be administered with or without food. Oral solution should be administered with a calibrated measuring device (not a household teaspoon or tablespoon). Oral solution may also be administered via a nasogastric or gastrostomy tube. Swallow tablets whole; do not divide. Swallow capsules whole; do not open, chew, or crush.</p></div>
<div class="block sts drugH1Div" id="F6790525"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Do not freeze. Stable when mixed with compatible diluents (NS, LR, D5W) for up to 4 hours at room temperature; extended storage information for prepared solution at room temperature may be available; contact product manufacturer to obtain current recommendations. Discard any unused portion.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution, tablets, capsule: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Do not freeze oral solution. Discard any unused portion of oral solution after 6 months.</p></div>
<div class="block meg drugH1Div" id="F7874836"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Motpoly XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F216185s000lbl.pdf%23page%3D22&amp;token=FlXgzJdIWhkh9CSkzEpuCpQa7ZhlF7FEIlLk5AOmrQ%2BrZijWi0kSv8IZE7G7mr9dRDI0Q8MT64qqXwZZz4aWEkqHuKJs2ydjkizxwBg5VMuYSgzUEEinWQypsbkM0n2o&amp;TOPIC_ID=83877" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216185s000lbl.pdf#page=22</a></p>
<p style="text-indent:-2em;margin-left:4em;">Vimpat: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022253s057%2C022254s047%2C022255s039lbl.pdf%23page%3D31&amp;token=ojHvE9WInNlgZWfmo0lxhj4GsBruF68%2BRKBXDHMbq9Ht1n%2BbdrbYviDndwv8CYwpqhLBX1Ox2jqPz9JFS%2FyjmRzhuciOdHS9CCdEDwx7fkAWR%2BRW5mD0VwYKAzKd302g&amp;TOPIC_ID=83877" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022253s057,022254s047,022255s039lbl.pdf#page=31</a></p></div>
<div class="block usep drugH1Div" id="F53570317"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release (eg, Vimpat): Treatment (monotherapy or adjunctive) of partial-onset seizures (FDA approved in ages ≥1 month and adults); adjunctive treatment of primary generalized tonic-clonic seizures (All indications: FDA approved in ages ≥4 years and adults); has also been used for treatment of refractory seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (eg, Motpoly XR): Treatment of partial-onset seizures (FDA approved in pediatric patients weighing ≥50 kg and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Injection (eg, Vimpat): Treatment (monotherapy or adjunctive) of partial-onset seizures (FDA approved in ages ≥1 month and adults); adjunctive treatment of primary generalized tonic-clonic seizures (All indications: FDA approved in ages ≥4 years and adults); has also been used for treatment of refractory seizures and refractory status epilepticus.</p></div>
<div class="block mst drugH1Div" id="F6790305"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lacosamide may be confused with zonisamide</p>
<p style="text-indent:-2em;margin-left:4em;">Vimpat may be confused with Venofer, Vfend, Vimovo</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299564"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F6802892"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiarrhythmic Agents (Class III): May enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiseizure Agents (Sodium Channel Blockers): May enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the AV-blocking effect of Lacosamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): May enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: May enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F6790651"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block pri drugH1Div" id="F6790315"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Lacosamide crosses the placenta (Ylikotila 2015; Zárubová 2016) and can be detected in the newborn serum at delivery (Landmark 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of lacosamide during pregnancy are limited (Golembesky 2017; Hoeltzenbein 2011; Lattanzi 2017; Zárubová 2016; Zutshi 2021). In general, maternal polytherapy with antiseizure drugs may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended. Newborns of patients taking antiseizure medications during pregnancy may be at an increased risk of adverse events (Harden 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of lacosamide may be altered (Fukushima 2021; Pennell 2022; Zárubová 2016; Zutshi 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to lacosamide is ongoing. Patients exposed to lacosamide during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at http://www.aedpregnancyregistry.org.</p></div>
<div class="block mopp drugH1Div" id="F53570320"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Seizure frequency, duration, and severity; patients with conduction problems, sodium channelopathies, severe cardiac disease, or concomitant medications that affect cardiac conduction or prolong the PR interval should have ECG tracing prior to start of therapy and when at steady-state; monitor heart rate and blood pressure during IV administration (bradycardia, atrioventricular block, or ventricular tachyarrhythmias may occur during infusions); monitor hepatic and renal function; suicidality (eg, suicidal thoughts, depression, behavioral changes).</p></div>
<div class="block rerp drugH1Div" id="F55967129"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic reference range: <b>Note:</b> There is no clear correlation with therapeutic concentrations and efficacy or tolerability and suggested therapeutic ranges vary depending on source; base dosing on therapeutic response as opposed to serum concentrations (AGNP [Hiemke 2018]; Patsalos 2018). However, therapeutic drug monitoring may be useful in pediatric patients, females, and patients receiving drugs that may interact with lacosamide (Contin 2013; Larsen Burns 2019; May 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Seizures</i>: 1 to 10 mcg/mL (SI: 2.66 to 26.6 micromole/L) (AGNP [Hiemke 2018]) <b>or</b> 10 to 20 mcg/mL (SI: 40 to 80 micromole/L) (Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples: Draw trough at steady-state, at the end of the scheduled dosing interval (just before the next dose).</p></div>
<div class="block pha drugH1Div" id="F6790564"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">In vitro studies have shown that lacosamide stabilizes hyperexcitable neuronal membranes and inhibits repetitive neuronal firing by enhancing the slow inactivation of sodium channels.</p></div>
<div class="block phk drugH1Div" id="F6790566"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~0.6 to 0.67 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;15%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4, CYP2C9, and CYP2C19; forms metabolite, O-desmethyl-lacosamide (inactive).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~100%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Mean weight 11 kg: 7.4 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Mean weight 28.9 kg: 10.6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Mean weight 70 kg: 14.8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~13 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: Immediate release (tablets, oral solution): 1 to 4 hours; extended release (capsules): 7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (95%; 40% as unchanged drug, 30% as inactive metabolite, 20% as uncharacterized metabolite); feces (&lt;0.5%).</p></div>
<div class="block phksp drugH1Div" id="F51198083"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC is increased ~25% in patients with mild or moderate renal impairment (CrCl &gt;30 to 80 mL/minute) and 60% in patients with severe renal impairment (CrCl ≤30 mL/minute). Following a 4-hour hemodialysis treatment, AUC is reduced by ~50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC is increased by ~50% to 60% in patients with moderate hepatic impairment (Child-Pugh class B).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In patients &gt;65 years of age, AUC and C<sub>max</sub> are increased ~20% compared with younger subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961941"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aldinam | Anacet | Comil | Lacomax | Lacotem | Vimpat</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lacopat | Lacosamid | Lacosamid genericon | Lacosamid hcs | Lacosamid ratiopharm | Lacosamid stada | Lacosamid UCB | Lacosamid zentiva | Lacosamide accord | Lacosamide aristo | Vimpat</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lacoress | Lacosam | Lacosamide arx | Lacosamide lupin | Lacosamide sandoz | Vimcosa | Vimpat</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide ab | Lacosamide eg | Vimpat</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Kanilad | Seizpat | Trelema | Vimpat</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lacosamida | Lacotem | Lapsu | Seizla | Vimpat</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lacosamid mepha | Vimpat</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aldinam | Entaxar | Lacosamida | Vimpat</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Apilep | Benvida | Cosamide | Lacolep | Lacosamida | Lacotem | Lakomid | Lancovul | Lenizad | Neuromid | Vimpat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Arkvimma | Kanilad | Lacosamide accord | Lacosamide Glenmark | Midza | Trelema | Vimpat</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lacosamid aaa pharma | Lacosamid ascend | Lacosamid desitin | Vimpat</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dualmida | Lacosan | Lacotem</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Comil 100 | Comil 150 | Comil 200 | Comil 50 | Cosalid 100 | Cosalid 200 | Cosalid 50 | Cosamide | Lacotem | Vimpat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Andovimpamide | Lacomadel | Lacosamet | Lacosanad | Lacosavil | Lacovimp | Vimpat</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cesiva | Lacosamida alter | Lacosamida aurovitas | Lacosamida cinfa | Lacosamida combix | Lacosamida krka | Lacosamida stada | Lacosamida teva | Lacosamida viso farmaceutica | Lacosamide aristo | Lacosamide normon | Lacosamide tecnigen | Lacosamide Zentiva | Laprysta | Vilepsia | Vimpat</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide accord | Lacosamide stada | Vimpat</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide accord | Lacosamide arrow | Lacosamide biogaran | Lacosamide eg | Lacosamide sandoz | Lacosamide teva | Lacosamide viatris | Lacosamide Zentiva | Vimpat</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eplaid | Lacosamide accord | Lacosamide amarox | Lacosamide aristo | Lacosamide aspire | Lacosamide dr. reddy's | Lacosamide g.l. pharma gmbh | Lacosamide macleods | Lacosamide milpharm | Lacosamide Zentiva | Vimpat</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Josamec | Kanilad | Lacosamide teva | Seizpat | Vimpat</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lakozamid Accord | Lakozamid Pliva | Seizpat | Vimpat</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cosim | Lacosamid teva | Trelema | Vimpat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide accord | Lacosamide krka | Vimpat</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Emsilac | Ictrol | Joseiz | Lacasa | Lacobris | Laconext | Lacopsy | Lacoptal | Lacosam | Lacosern | Lacoset | Lacosure | Lacove | Lacoxa | Licotar | Seizgard | Seizlac | Sizlac | Versolac</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Lacomide</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide accord | Lacosamide aristo | Lacosamide aurobindo | Lacosamide doc | Lacosamide eg | Lacosamide krka | Lacosamide mylan | Lacosamide sandoz | Lacosamide teva | Lacosamide Zentiva | Laprysta | Nepilex | Stutan | Vimpat</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Trepadio | Vimpat</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cosamide | Lacasa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Laco | Lacopat | Laxarotin | Neopat | Vimcosa | Vimpat | Vimpro | Vimsc | Vimsk</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Kanilad | Vimpat</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kanilad | Lacosamide teva | Vimpat</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Copinar | Elunei | Kuryent | Lacosamida | Vimpat</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide accord | Lacosamide Glenmark | Lacosamide mylan | Lacosamide neuraxpharm | Lacosamide sandoz | Lacosamide xiromed | Vimpat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide accord | Lacosamide medical valley | Vimpat</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aldinam | Lacotem</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atcomid | Clipsel | Cosamid | L mide | Lacogit | Lacolep | Lacolit | Lacom | Lacomide | Lacos | Lacosa | Lacosam | Lacosave | Lacosbar | Lacost | Lacosta | Lacoswrd | Lacotab | Lacova | Lakill | Lakosa | Lalap | Lalik | Lecomide | Lecoz | Leonda | Limpat | Lusam | Nurosa | Nurotic | Posnil | Ridomide | Samide | Semide | Sezamide | Solap | Tcosmid | Tisamide | Vicomid | Vimpex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Arkvimma | Cosim | Epilac | Lackepila | Lacosamide accord | Lacosamide Glenmark | Lacosamide teva | Lacosamide Zentiva | Seizpat | Trelema | Vimpat</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lacosamida accord | Lacosamida aristo | Lacosamida generis | Lacosamida intas | Lacosamida mylan | Lacosamida ratiopharm | Lacosamida zentiva | Vimpat</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aldinam | Lacotem</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lacosamida | Vimpat</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide spc | Lazure | Trepadio | Vimpat</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide accord | Lacosamide krka | Lacosamide stada | Lacosamide teva | Lacosamide Zentiva | Vimpat</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lacosamide accord | Lakozamid teva | Losmorid | Midza | Vimpat</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Arkvimma | Kanilad | Lacosamide accord | Midza | Seizpat | Trelema | Vimpat</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Benvida | Elepsi | Lamide | Vimpat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lacosam</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Cosamide</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Entaxar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Vimpat</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cosamide</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Cosamide</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21354831">
<a name="21354831"></a>Albers JM, Möddel G, Dittrich R, et al. Intravenous lacosamide—an effective add-on treatment of refractory status epilepticus. <i>Seizure</i>. 2011;20(5):428-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/21354831/pubmed" id="21354831" target="_blank">21354831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818889">
<a name="20818889"></a>Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. <i>N Engl J Med</i>. 2010 5;363(6):542-551. doi:10.1056/NEJMoa0909801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/20818889/pubmed" id="20818889" target="_blank">20818889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26810009">
<a name="26810009"></a>Arkilo D, Gustafson M, Ritter FJ. Clinical experience of intravenous lacosamide in infants and young children. <i>Eur J Paediatr Neurol</i>. 2016;20(2):212-217. doi:10.1016/j.ejpn.2015.12.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/26810009/pubmed" id="26810009" target="_blank">26810009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990368">
<a name="31990368"></a>Ayuga Loro F, Gisbert Tijeras E, Brigo F. Rapid versus slow withdrawal of antiepileptic drugs. <i>Cochrane Database Syst Rev</i>. 2020;1(1):CD005003. doi:10.1002/14651858.CD005003.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/31990368/pubmed" id="31990368" target="_blank">31990368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27889312">
<a name="27889312"></a>Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial [published correction appears in <i>Lancet Neurol</i>. 2017;16(2):102]. <i>Lancet Neurol</i>. 2017;16(1):43-54. doi:10.1016/S1474-4422(16)30292-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/27889312/pubmed" id="27889312" target="_blank">27889312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453718">
<a name="19453718"></a>Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk? <i>Epilepsia</i>. 2009;50(8):1933-1942. doi:10.1111/j.1528-1167.2009.02106.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/19453718/pubmed" id="19453718" target="_blank">19453718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28190254">
<a name="28190254"></a>Bellivier F, Belzeaux R, Scott J, Courtet P, Golmard JL, Azorin JM. Anticonvulsants and suicide attempts in bipolar I disorders. <i>Acta Psychiatr Scand</i>. 2017;135(5):470-478. doi:10.1111/acps.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/28190254/pubmed" id="28190254" target="_blank">28190254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi: 10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635557">
<a name="17635557"></a>Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. <i>Epilepsia.</i> 2007;48(7):1308-1317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/17635557/pubmed" id="17635557" target="_blank">17635557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28343443">
<a name="28343443"></a>Berei TJ, Lillyblad MP, Almquist AK. Lacosamide-induced recurrent ventricular tachycardia in the acute care setting. <i>J Pharm Pract</i>. 2018;31(2):222-226. doi:10.1177/0897190017700557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/28343443/pubmed" id="28343443" target="_blank">28343443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23193979">
<a name="23193979"></a>Casas-Fernández C, Martínez-Bermejo A, Rufo-Campos M, et al. Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain. <i>Drugs R D</i>. 2012;12(4):187-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23193979/pubmed" id="23193979" target="_blank">23193979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737404">
<a name="23737404"></a>Cawello W, Fuhr U, Hering U, Maatouk H, Halabi A. Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide. <i>Clin Pharmacokinet</i>. 2013;52(10):897-906. doi:10.1007/s40262-013-0080-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23737404/pubmed" id="23737404" target="_blank">23737404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23360388">
<a name="23360388"></a>Chinnasami S, Rathore C, Duncan JS. Sinus node dysfunction: an adverse effect of lacosamide. <i>Epilepsia</i>. 2013;54(6):e90-e93. doi:10.1111/epi.12108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23360388/pubmed" id="23360388" target="_blank">23360388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20132285">
<a name="20132285"></a>Chung S, Sperling MR, Biton V, et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. <i>Epilepsia</i>. 2010;51(6):958-967. doi:10.1111/j.1528-1167.2009.02496.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/20132285/pubmed" id="20132285" target="_blank">20132285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23942540">
<a name="23942540"></a>Contin M, Albani F, Riva R, Candela C, Mohamed S, Baruzzi A. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. <i>Ther Drug Monit</i>. 2013;35(6):849-852. doi:10.1097/FTD.0b013e318290eacc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23942540/pubmed" id="23942540" target="_blank">23942540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29949010">
<a name="29949010"></a>Davidson KE, Newell J, Alsherbini K, Krushinski J, Jones GM. Safety and efficiency of intravenous push lacosamide administration. <i>Neurocrit Care</i>. 2018;29(3):491-495. doi:10.1007/s12028-018-0560-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/29949010/pubmed" id="29949010" target="_blank">29949010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25688050">
<a name="25688050"></a>DeGiorgio AC, Desso TE, Lee L, DeGiorgio CM. Ventricular tachycardia associated with lacosamide co-medication in drug-resistant epilepsy. <i>Epilepsy Behav Case Rep</i>. 2012;1:26-28. doi:10.1016/j.ebcr.2012.10.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/25688050/pubmed" id="25688050" target="_blank">25688050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462582">
<a name="31462582"></a>Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. <i>Neurology</i>. 2019;93(12):e1212-e1226. doi:10.1212/WNL.0000000000008126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/31462582/pubmed" id="31462582" target="_blank">31462582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30723940">
<a name="30723940"></a>Farrokh S, Bon J, Erdman M, Tesoro E. Use of newer anticonvulsants for the treatment of status epilepticus. <i>Pharmacotherapy</i>. 2019;39(3):297-316. doi:10.1002/phar.2229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/30723940/pubmed" id="30723940" target="_blank">30723940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22698379">
<a name="22698379"></a>Flores L, Kemp S, Colbeck K, et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK). <i>Seizure</i>. 2012;21(7):512-517. doi:10.1016/j.seizure.2012.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/22698379/pubmed" id="22698379" target="_blank">22698379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29588957">
<a name="29588957"></a>Fong MK, Sheng B. DRESS syndrome: A case of cross-reactivity with lacosamide? <i>Epilepsia Open</i>. 2017;2(2):273-275. doi:10.1002/epi4.12053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/29588957/pubmed" id="29588957" target="_blank">29588957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22708895">
<a name="22708895"></a>Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd GD. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures. <i>Epilepsia</i>. 2013;54(1):58‐65. doi:10.1111/j.1528-1167.2012.03543.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/22708895/pubmed" id="22708895" target="_blank">22708895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29160945">
<a name="29160945"></a>Franquiz MJ, Kalaria SN, Armahizer MJ, Gopalakrishnan M, McCarthy PJ, Badjatia N. Lacosamide pharmacokinetics in a critically ill patient receiving continuous venovenous hemofiltration. <i>Pharmacotherapy</i>. 2018;38(2):e17-e21. doi:10.1002/phar.2063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/29160945/pubmed" id="29160945" target="_blank">29160945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33774498">
<a name="33774498"></a>Fukushima Y, Yamamoto Y, Yamazaki E, et al. Change in the pharmacokinetics of lacosamide before, during, and after pregnancy. <i>Seizure</i>. 2021;88:12-14. doi:10.1016/j.seizure.2021.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/33774498/pubmed" id="33774498" target="_blank">33774498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21406334">
<a name="21406334"></a>Gavatha M, Ioannou I, Papavasiliou AS. Efficacy and Tolerability of Oral Lacosamide as Adjunctive Therapy in Pediatric Patients With Pharmacoresistant Focal Epilepsy. <i>Epilepsy Behav.</i> 2011;20(4):691-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/21406334/pubmed" id="21406334" target="_blank">21406334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golembesky.1">
<a name="Golembesky.1"></a>Golembesky A, Cooney M, Craig J, et al. Outcomes following exposure to the antiepileptic drug lacosamide during pregnancy – results from a global safety database (p5.231). <i>Neurology</i>. 2017;88(16):1-6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21249530">
<a name="21249530"></a>Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ 3rd. The use of lacosamide in refractory status epilepticus. <i>Neurocrit Care</i>. 2011;14(3):348-353. doi:10.1007/s12028-010-9501-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/21249530/pubmed" id="21249530" target="_blank">21249530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24479878">
<a name="24479878"></a>Grosso S, Coppola G, Cusmai R, et al. Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome. <i>Acta Neurol Scand</i>. 2014a;129(6):420-424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/24479878/pubmed" id="24479878" target="_blank">24479878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24129195">
<a name="24129195"></a>Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. <i>Eur J Paediatr Neurol</i>. 2014b;18(1):55-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/24129195/pubmed" id="24129195" target="_blank">24129195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24836405">
<a name="24836405"></a>Grosso S, Zamponi N, Bartocci A, et al. Lacosamide in children with refractory status epilepticus. A multicenter Italian experience. <i>Eur J Paediatr Neurol</i>. 2014c;18(5):604-608. doi:10.1016/j.ejpn.2014.04.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/24836405/pubmed" id="24836405" target="_blank">24836405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19183227">
<a name="19183227"></a>Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. <i>Epilepsia</i>. 2009;50(3):443‐453. doi:10.1111/j.1528-1167.2008.01951.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/19183227/pubmed" id="19183227" target="_blank">19183227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496806">
<a name="19496806"></a>Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? <i>Epilepsia</i>. 2009;50(5):978-986. doi:10.1111/j.1528-1167.2009.02012.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/19496806/pubmed" id="19496806" target="_blank">19496806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017 [published correction appears in <i>Pharmacopsychiatry</i>. 2018;51(1-02):e1]. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hoeltzenbein.1">
<a name="Hoeltzenbein.1"></a>Hoeltzenbein M, Supcun-Ritzler S, Langthaler M, et al. Lacosamide During pregnancy: Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. <i>Reprod Toxicol.</i> 2011;31(2):259.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23293881">
<a name="23293881"></a>Höfler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. <i>Epilepsia</i>. 2013;54(3):393-404. doi:10.1111/epi.12058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23293881/pubmed" id="23293881" target="_blank">23293881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jirsch.1">
<a name="Jirsch.1"></a>Jirsch J, Hirsch LJ. Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33855736">
<a name="33855736"></a>Kalaria SN, Armahizer M, McCarthy P, Badjatia N, Gobburu JV, Gopalakrishnan M. A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE-02). <i>Br J Clin Pharmacol</i>. 2021;87(11):4375-4385. doi:10.1111/bcp.14858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/33855736/pubmed" id="33855736" target="_blank">33855736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27017922">
<a name="27017922"></a>Kardaun SH, Vos BJ, Chandran NS. Stevens Johnson syndrome/toxic epidermal necrolysis-overlap, induced by lacosamide. <i>Eur J Dermatol</i>. 2016;26(2):185-186. doi:10.1684/ejd.2015.2674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/27017922/pubmed" id="27017922" target="_blank">27017922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19816574">
<a name="19816574"></a>Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. <i>Ther Clin Risk Manag</i>. 2009;5:757-766. doi:10.2147/tcrm.s5189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/19816574/pubmed" id="19816574" target="_blank">19816574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20868429">
<a name="20868429"></a>Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. <i>Acta Neurol Scand</i>. 2011;123(2):137-141. doi:10.1111/j.1600-0404.2010.01423.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/20868429/pubmed" id="20868429" target="_blank">20868429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18698874">
<a name="18698874"></a>Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. <i>CNS Drugs</i>. 2008;22(9):739-760. doi:10.2165/00023210-200822090-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/18698874/pubmed" id="18698874" target="_blank">18698874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31997613">
<a name="31997613"></a>Kim HK, Kim DY, Bae EK, Kim DW. Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008-2017. <i>J Korean Med Sci</i>. 2020;35(4):e17. doi:10.3346/jkms.2020.35.e17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/31997613/pubmed" id="31997613" target="_blank">31997613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25035958">
<a name="25035958"></a>Koubeissi MZ, Vismer M, Ehrlich A. Lacosamide-induced rash. <i>Epileptic Disord</i>. 2014;16(3):380-383. doi:10.1684/epd.2014.0667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/25035958/pubmed" id="25035958" target="_blank">25035958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33935028">
<a name="33935028"></a>Landmark CJ, Rektorli L, Burns ML, et al. Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation. <i>Epileptic Disord</i>. 2021;23(2):426-431. doi:10.1684/epd.2021.1273<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/33935028/pubmed" id="33935028" target="_blank">33935028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30688870">
<a name="30688870"></a>Larsen Burns M, Nikanorova M, Baftiu A, et al. Pharmacokinetic variability and clinical use of lacosamide in children and adolescents in Denmark and Norway. <i>Ther Drug Monit</i>. 2019;41(3):340-347. doi:10.1097/FTD.0000000000000599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/30688870/pubmed" id="30688870" target="_blank">30688870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28385340">
<a name="28385340"></a>Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide during pregnancy and breastfeeding. <i>Neurol Neurochir Pol</i>. 2017;51(3):266-269. doi:10.1016/j.pjnns.2017.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/28385340/pubmed" id="28385340" target="_blank">28385340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31914330">
<a name="31914330"></a>Li J, Sun M, Wang X. The adverse-effect profile of lacosamide. <i>Expert Opin Drug Saf</i>. 2020;19(2):131-138. doi:10.1080/14740338.2020.1713089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/31914330/pubmed" id="31914330" target="_blank">31914330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32524876">
<a name="32524876"></a>Madani N, O'Malley JA, Porter BE, Baumer FM. Lacosamide-induced dyskinesia in children with intractable epilepsy. <i>J Child Neurol</i>. 2020;35(10):662-666. doi:10.1177/0883073820926634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/32524876/pubmed" id="32524876" target="_blank">32524876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30086089">
<a name="30086089"></a>May TW, Helmer R, Bien CG, Brandt C. Influence of dose and antiepileptic comedication on lacosamide serum concentrations in patients with epilepsy of different ages. <i>Ther Drug Monit</i>. 2018;40(5):620-627. doi:10.1097/FTD.0000000000000538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/30086089/pubmed" id="30086089" target="_blank">30086089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27430392">
<a name="27430392"></a>McGinnis E, Kessler SK. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort. <i>Epilepsia</i>. 2016;57(9):1416-1425. doi:10.1111/epi.13466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/27430392/pubmed" id="27430392" target="_blank">27430392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27086495">
<a name="27086495"></a>Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-johnson syndrome and toxic epidermal necrolysis: An analysis of triggers and implications for improving prevention. <i>Am J Med</i>. 2016;129(11):1221-1225. doi:10.1016/j.amjmed.2016.03.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/27086495/pubmed" id="27086495" target="_blank">27086495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28919386">
<a name="28919386"></a>Misra UK, Dubey D, Kalita J. Comparison of lacosamide versus sodium valproate in status epilepticus: a pilot study. <i>Epilepsy Behav.</i> 2017;76:110. doi:10.1016/j.yebeh.2017.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/28919386/pubmed" id="28919386" target="_blank">28919386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Motpoly.1">
<a name="Motpoly.1"></a>Motpoly XR (lacosamide) injection, oral solution, tablet [prescribing information]. Piscataway, NJ: Aucta Pharmaceuticals Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21753899">
<a name="21753899"></a>Mula M, Hesdorffer DC. Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence. <i>Drug Healthc Patient Saf</i>. 2011;3:15-20. doi:10.2147/DHPS.S13070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/21753899/pubmed" id="21753899" target="_blank">21753899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22994856">
<a name="22994856"></a>Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. <i>Epilepsia</i>. 2013;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/22994856/pubmed" id="22994856" target="_blank">22994856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27844464">
<a name="27844464"></a>Newey CR, Le NM, Ahrens C, Sahota P, Hantus S. The safety and efficacy of intravenous lacosamide for refractory status epilepticus in the critically ill. <i>Neurocrit Care.</i> 2017;26(2):273-279. doi:10.1007/s12028-016-0322-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/27844464/pubmed" id="27844464" target="_blank">27844464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management of drug allergy in adults, children and young people. Published September 2014. Accessed November 11, 2021. https://www.nice.org.uk/guidance/cg183
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/27844464/pubmed" id="27844464" target="_blank">27844464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29428899">
<a name="29428899"></a>Ortiz de la Rosa JS, Ladino LD, Rodríguez PJ, Rueda MC, Polanía JP, Castañeda AC. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: a systematic review. <i>Seizure</i>. 2018;56:34-40. doi:10.1016/j.seizure.2018.01.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/29428899/pubmed" id="29428899" target="_blank">29428899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi:10.1097/FTD.0000000000000546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20388896">
<a name="20388896"></a>Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. <i>JAMA</i>. 2010;303(14):1401-1409. doi:10.1001/jama.2010.410. Erratum in: <i>JAMA</i>. 2010;303(22):2252. Dosage error in article text.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/20388896/pubmed" id="20388896" target="_blank">20388896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35157004">
<a name="35157004"></a>Pennell PB, Karanam A, Meador KJ, et al; MONEAD Study Group. Antiseizure medication concentrations during pregnancy: results from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study. <i>JAMA Neurol</i>. 2022;79(4):370-379. doi:10.1001/jamaneurol.2021.5487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/35157004/pubmed" id="35157004" target="_blank">35157004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22832500">
<a name="22832500"></a>Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. <i>Lancet Neurol</i>. 2012;11(9):792-802. doi:10.1016/S1474-4422(12)70153-9. Erratum in: <i>Lancet Neurol</i>. 2012;11(9):746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/22832500/pubmed" id="22832500" target="_blank">22832500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27241232">
<a name="27241232"></a>Poddar K, Sharma R, Ng YT. Intravenous lacosamide in pediatric status epilepticus: an open-label efficacy and safety study. <i>Pediatr Neurol</i>. 2016;61:83-86. doi:10.1016/j.pediatrneurol.2016.03.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/27241232/pubmed" id="27241232" target="_blank">27241232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275630">
<a name="30275630"></a>Rao NP, Sheth S, Varambally S. Lacosamide precipitated neutropenia in a patient with bipolar disorder and comorbid epilepsy. <i>Indian J Psychol Med</i>. 2018;40(5):496-497. doi:10.4103/IJPSYM.IJPSYM_16_18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/30275630/pubmed" id="30275630" target="_blank">30275630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25933358">
<a name="25933358"></a>Rudd GD, Haverkamp W, Mason JW, et al. Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures. <i>Acta Neurol Scand</i>. 2015;132(5):355-363. doi:10.1111/ane.12414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/25933358/pubmed" id="25933358" target="_blank">25933358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34102997">
<a name="34102997"></a>Shibata M, Hoshino R, Shimizu C, Sato M, Furuta N, Ikeda Y. Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis. <i>BMC Neurol</i>. 2021;21(1):217. doi:10.1186/s12883-021-02253-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/34102997/pubmed" id="34102997" target="_blank">34102997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27054272">
<a name="27054272"></a>Steinhoff BJ, Eckhardt K, Doty P, De Backer M, Brunnert M, Schulze-Bonhage A. A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures. <i>Epilepsy Behav</i>. 2016;58:35-43. doi:10.1016/j.yebeh.2016.02.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/27054272/pubmed" id="27054272" target="_blank">27054272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28295226">
<a name="28295226"></a>Strzelczyk A, Zöllner JP, Willems LM, et al. Lacosamide in status epilepticus: systematic review of current evidence. <i>Epilepsia</i>. 2017;58(6):933-950. doi:10.1111/epi.13716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/28295226/pubmed" id="28295226" target="_blank">28295226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23533010">
<a name="23533010"></a>Sutter R, Marsch S, Rüegg S. Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study. <i>CNS Drugs</i>. 2013;27(4):321-329. doi:10.1007/s40263-013-0049-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23533010/pubmed" id="23533010" target="_blank">23533010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298605">
<a name="23298605"></a>Verrotti A, Loiacono G, Pizzolorusso A, et al. Lacosamide in pediatric and adult patients: comparison of efficacy and safety. <i>Seizure</i>. 2013;22(3):210-216. doi:10.1016/j.seizure.2012.12.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23298605/pubmed" id="23298605" target="_blank">23298605</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vimpat (lacosamide) injection, oral solution, tablet [prescribing information]. Smyrna, GA: UCB Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vimpat.1">
<a name="Vimpat.1"></a>Vimpat (lacosamide) injection, tablets [product monograph]. Oakville, Ontario, Canada: UCB Canada Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32822230">
<a name="32822230"></a>Vossler DG, Bainbridge JL, Boggs JG, et al. Treatment of refractory convulsive status epilepticus: a comprehensive review by the American Epilepsy Society Treatments Committee. <i>Epilepsy Curr</i>. 2020;20(5):245-264. doi:10.1177/1535759720928269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/32822230/pubmed" id="32822230" target="_blank">32822230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24915838">
<a name="24915838"></a>Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. <i>Epilepsia</i>. 2014;55(7):1088‐1098. doi:10.1111/epi.12681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/24915838/pubmed" id="24915838" target="_blank">24915838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29017081">
<a name="29017081"></a>Welsh SS, Lin N, Topjian AA, Abend NS. Safety of intravenous lacosamide in critically ill children. <i>Seizure</i>. 2017;52:76-80. doi:10.1016/j.seizure.2017.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/29017081/pubmed" id="29017081" target="_blank">29017081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26077821">
<a name="26077821"></a>Weston J, Shukralla A, McKay AJ, Marson AG. Lacosamide add-on therapy for partial epilepsy. <i>Cochrane Database Syst Rev</i>. 2015;(6):CD008841. doi:10.1002/14651858.CD008841.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/26077821/pubmed" id="26077821" target="_blank">26077821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26187779">
<a name="26187779"></a>Ylikotila P, Ketola RA, Timonen S, Malm H, Ruuskanen JO. Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. <i>Reprod Toxicol</i>. 2015;57:204-206. doi:10.1016/j.reprotox.2015.07.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/26187779/pubmed" id="26187779" target="_blank">26187779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zarubova.1">
<a name="Zarubova.1"></a>Zárubová J, Kremlackova V, Borecka K, et al. Plasma and breast milk levels of lacosamide before, during and post pregnancy. <i>Epilepsia</i>. 2016;57(suppl 2):69. Abstract. doi:10.1111/epi.13609</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34905638">
<a name="34905638"></a>Zhao X, Liu Y, Xu Z. A paediatric case of lacosamide-induced panniculitis. <i>Australas J Dermatol</i>. 2022;63(1):e107-e109. doi:10.1111/ajd.13763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/34905638/pubmed" id="34905638" target="_blank">34905638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34399392">
<a name="34399392"></a>Zutshi D, Millis SR, Basha MM, Daimee MA, Srinivas M. Lacosamide serum concentrations during pregnancy. <i>Epilepsy Behav</i>. 2021;123:108253. doi:10.1016/j.yebeh.2021.108253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/34399392/pubmed" id="34399392" target="_blank">34399392</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 83877 Version 404.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
